Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval as 1L Treatment of Locally Advanced or Metastatic Urothelial Cancer
Shots: The US FDA has approved Merck’s Keytruda (anti-PD-1 therapy) in combination with Padcev for adult patients with LA/mUC who are not eligible for cisplatin-containing […]